<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143219</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-N-2014-01</org_study_id>
    <secondary_id>2014-000539-17</secondary_id>
    <nct_id>NCT02143219</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer</brief_title>
  <acronym>PAMELA70</acronym>
  <official_title>Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) of &quot;FOLFIRINOX &quot; Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yo. or Older) With a Metastatic Pancreatic Adenocarcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metastatic pancreatic carcinomas represent the 5th cause of cancer death in France (#8000 per
      year). The median age at diagnosis is 69 and 74 in male and female respectively. When the
      5-Fluorouracile has been used as a single agent with a limited efficacy during more than 20
      years, the onset of gemcitabine in 1995 has led to a moderate increase of median survival
      (from 4.41 to 5.65 months) and overall survival at 1 year (2 versus 18%). Recently, in a
      phase II followed by a phase-III study, a French collaborative group has demonstrated the
      benefit of &quot;FOLFIRINOX &quot; regimen versus gemcitabine alone, in terms of median survival (11.1
      versus 6.8 months), progression-free survival (6.4 versus 3.3 months) and response rate (31.6
      versus 9.4%).

      Although more hematologic (neutropenia) and GI toxicities were observed, FOLFIRINOX was
      acceptable as a new standard regimen for the majority of patients under the age of 70 with a
      good Performans Status. To reduce the toxicity of FOLFIRINOX in elderly patients (&gt; 70 yo),
      pharmacogenetic monitoring of 5-FU and Irinotecan key metabolism enzymes (DPD and UGTA1) may
      be easily performed. The methodology of the study is to use the Bryant &amp; Day statistical
      method, allowing to consider simultaneously as principal objective, the response rate
      (efficacy) and the tolerance (preservation of autonomy daily living, Katz index): this design
      is particularly fitting in a study for elderly patients who represent half of the pancreatic
      carcinoma population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      METHODOLOGY :

      Phase II study, opened, multicentric

      MAIN OBJECTIVE :

      The main objective is the simultaneous evaluation of the objective rate of answer and
      toxicity of her(it) of the protocol FOLFIRINOX administered to doses adapted at patients of
      70 and more years old.

      SECONDARY OBJECTIVE :

        -  Efficiency evaluation;

        -  Tolerance evaluation;

        -  Quality of Life (QoL) and clinical profit.

      STATISTICAL ANALYSIS:

      An analysis in two stages is planned, according to the method of Bryant and Day with a risk ß
      5 % to reject wrongly an effective treatment and of acceptable toxicity and a risk a=10 % to
      accept wrongly a not rather effective or too toxic treatment.

      The study will be considered as successful if:

        -  we obtain at least 11 tumoral answers and

        -  maxi 30 patients on 72 are in loss of autonomy (decrease of their ADL).

             -  All the patients who will have received at least an injection will be eligible for
                the evaluation of the toxicity

             -  The evaluation of the efficiency will be made after 3 cures at least unless early
                termination where the scanner will be anticipated.

             -  All the toxicity will be increased according to criteria of toxicity NCI-CTC v4.0.

             -  The evaluation of the tumoral answer (CR, PR and SD) will be made according to the
                criteria RECIST-v1.1.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1st step analysis : Safety and efficacy after 34 patients included</measure>
    <time_frame>12 weeks after the 34th patient included</time_frame>
    <description>Evaluation of Efficacy: Progression-free-Survival (PFS) and Overall Survival (OS) will be evaluated.
Evaluation of Toxicity: Will be analyzed, according to the NCI-CTCAE version 4.0:
The incidence of hematological toxicities (grade 3-4, in particular neutropenia and febrile neutropenia)
The incidence of GI toxicities, in particular diarrhea and oral mucositis
The incidence of peripheral neuropathies
For statistical analysis :
either &gt;= 17 patients show a decrease of their ADL (of 1.5 ADL or more) : the treatment is considered as being too toxic, either &lt;= 3 patients presented a tumoral response: the treatment is considered as not being effective enough,
=&gt; The study will then be arrested in this 1st stage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2nd step analysis : Safety and efficacy after 72patients included</measure>
    <time_frame>12 weeks after the 72th patient included</time_frame>
    <description>Only if 1st step is successful we can do the second step :
For toxicity : if &gt;= 31patients show a decrease of their ADL (of 1.5 ADL or more) and/or
For efficacy : if &lt;= 10 patients presented a tumoral response
=&gt; Study is successful if :
we obtain at least 11 tumoral response and
maximum 30 patients on 72 evaluable are in loss of autonomy (ADL)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Pancreatic Metastatic Cancer</condition>
  <condition>Toxicity</condition>
  <arm_group>
    <arm_group_label>FOLFIRINOX</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FOLFIRINOX (D1-D15, for maximum 12 cycles) = Oxaliplatine + Folinic acid + Irinotecan + 5-FU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatine</intervention_name>
    <description>Oxaliplatine : 85mg/m², 2-hours IV infusion (D1), then,</description>
    <arm_group_label>FOLFIRINOX</arm_group_label>
    <other_name>Eloxatine®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic acid</intervention_name>
    <description>Folinic acid (FA): 400 mg/m² , 2-hour IV infusion (D1),</description>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan (at the dosage determined by the UGT1A1 status), 90 min IV infusion starting 30 min after the FA starts
Homozygous 6/6 or 6/7: irinotecan will start at 150 mg/m², then will be increased according to clinical/biological tolerance by 10% steps, at each cycle, up to 180 mg/m² at max.
Homozygous 7/7: irinotecan will start at 130 mg/m² in the first cycle then be increased up to a max of 150 mg/m², by 10% steps, according to tolerance.</description>
    <arm_group_label>FOLFIRINOX</arm_group_label>
    <other_name>Campto®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU (according to the DPD pharmacogenetic status), continuous IV infusion of 46 hours, starting at the end of FA infusion:
If no DPD deficiency, 5-FU start at 1600 mg/m² and can be modulated according to clinical/biological tolerance after each course, i.e., 1800 mg/m² the 2nd course and 2000 mg/m² the 3rd one
If partial DPD deficiency: 5-FU start at 1200 mg/m² and can be increased up to 1800, then 2000 if the clinical/biological tolerance are good at the 2nd and 3rd course.</description>
    <arm_group_label>FOLFIRINOX</arm_group_label>
    <other_name>5-fluorouracile</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven ductal pancreatic carcinoma

          -  Metastatic disease

          -  First-line treatment : No previous chemotherapy in metastatic stage but adjuvant
             treatment before relapse (secondary metastatic) is permitted, provide it has been
             administered more than 6 months before)

          -  Age of 70 yo or above

          -  Normal DPD enzyme level or partial defect (excluding total defect)

          -  Adequate bone marrow reserve: as indicated by : neutrophils &gt;1500/mm3, platelets
             &gt;100,000/ mm3, Hb &gt;10.0g/dL.

          -  Adequate Renal function as indicated by: MDRD creatinine clearance &gt; 50ml/min.

          -  Adequate hepatic function as indicated by: serum bilirubin &lt; 1.5 times the upper limit
             of normal, AST and ALT &lt; 2.5 times the upper limit of normal, or &lt; 5 times the upper
             limit of normal if liver metastases are present.

          -  Written informed consent must be obtained prior to protocol-specific procedures are
             being performed

          -  Patient is affiliated to a social security category

        Exclusion Criteria:

          -  Other than ductal pancreatic carcinoma: namely endocrin tumors, acinar cells
             carcinoma, cystadenocarcinoma or adenocarcinoma of the ampulla of vater

          -  Non-metastatic but locally advanced pancreatic adenocarcinoma

          -  Complete DPD deficiency

          -  History of Cardiac failure or symptomatic coronary artery disease

          -  Autonomy Daily Living score by Katz &lt;4

          -  Prior treatment with FOLFIRINOX (adjuvant)

          -  Major comorbidity likely to be an obstacle to treatment

          -  Active or uncontrolled infection such as HIV or chronic B or C hepatitis

          -  Uncontrolled diabetes mellitus

          -  Prior peripheral neuropathy, grade &gt; 2

          -  Inflammatory bowel disease localized on the colon or rectum; bowel obstruction or
             severe uncontrolled diarrhea

          -  Previous or concomitant malignancies other than effectively treated carcinoma in situ
             of the cervix or non-melanoma skin cancer

          -  Hereditary fructose intolerance

          -  Persons deprived of liberty or under guardianship

          -  Any social, geographical or psychological condition which would compromise the ability
             to fully comply with the trial procedures and treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandrine HIRET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de l'Ouest (ICO) - Nantes, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandrine HIRET, MD</last_name>
    <phone>+33 2 40 67 99 00</phone>
    <phone_ext>9357</phone_ext>
    <email>sandrine.hiret@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François PEIN, MD</last_name>
    <phone>+33 2 40 67 99 08</phone>
    <email>Francois.Pein@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CAPITAIN, MD</last_name>
      <phone>+33 2 41 35 27 00</phone>
      <email>olivier.capitain@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier CAPITAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Vendée</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roger FAROUX, MD</last_name>
      <phone>02 51 44 61 68</phone>
    </contact>
    <investigator>
      <last_name>Roger FAROUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile GARCEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morgane AMIL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François DEWAELE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Pierre LAFARGUE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthieu SCHNEE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent MACE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ADENIS, MD</last_name>
      <phone>03.20.29.55.00</phone>
    </contact>
    <investigator>
      <last_name>Antoine ADENIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farid EL HAJBI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric AMELA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte PEUGNIEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM (Val d'Aurelle)</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle SAMALIN, MD</last_name>
      <phone>04 67 67 25 92</phone>
    </contact>
    <investigator>
      <last_name>Emmanuel SAMALIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Blandine GALLET-SUCHET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence DALSTEIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc YCHOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO René Gauducheau</name>
      <address>
        <city>Nantes - St Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine HIRET, MD</last_name>
      <phone>+33 2 40 67 99 00</phone>
      <phone_ext>9357</phone_ext>
      <email>sandrine.hiret@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sandrine HIRET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Yves DOUILLARD, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaafar BENNOUNA, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène SENELLART, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugène marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bérengère LECONTE, MD</last_name>
      <phone>02 99 28 54 65</phone>
    </contact>
    <investigator>
      <last_name>Bérengère LECONTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelyne BOUCHER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain MANFREDI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien EDELINE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2014</study_first_submitted>
  <study_first_submitted_qc>May 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic metastatic cancer</keyword>
  <keyword>FOLFIRINOX</keyword>
  <keyword>toxicity</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

